Clinical trials
Relapsed Acute Myeloid Leukemia clinical trials
Below are recruiting relapsed acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06980155RecruitingEarly Phase 1
Personalized vaccine with or without toripalimab to prevent AML relapse
This trial tests a personalized cancer vaccine, alone or with an immunotherapy drug called toripalimab, to help keep acute myeloid leukemia (AML) in remission. It is for people who have finished initial treatment, are in remission, but still have some leukemia cells remaining (MRD positive) and have a specific NPM1 gene mutation.
ShanghaiAges 18 years+ - NCT06990321RecruitingPhase 3
Cytarabine and venetoclax for older adults with AML
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Changchun, JilinAges 60–75 - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Duarte, CaliforniaAges 12 years+ - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07107126RecruitingPhase 1
Testing a new drug for relapsed AML or high-risk MDS
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
New York, New YorkAges 18 years+ - NCT07144020RecruitingEarly Phase 1
Donor CAR-T cells for relapsed or refractory AML
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07238712RecruitingPhase 2
New drug combo for high-risk blood cancer transplant
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
Saint PetersburgAges 18–70 - NCT06234904RecruitingPhase 1
IBR733 cell therapy for acute myeloid leukemia
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Suzhou, JiangsuAges 18–74 - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT06812104RecruitingPhase 1
A trial of KK2845 for certain blood cancers
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
Kamogawa, ChibaAges 18 years+ - NCT04050280RecruitingPhase 2
Testing an antibody drug for relapsed or hard-to-treat AML
This trial studies a drug called CLAG-GO (an antibody with chemotherapy drugs attached) in adults with AML that has come back or did not respond to treatment. It aims to improve outcomes for people whose leukemia is persistent, relapsed, or refractory.
Baltimore, MarylandAges 18 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Birmingham, AlabamaAges 18 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT02390635RecruitingPhase 1
Testing PET/MRI scans to find leukemia outside the bone marrow
This Phase 1 study uses special whole-body imaging scans (PET with CT, plus MRI) to look for signs of acute myeloid leukemia outside the bone marrow. It may help doctors better see where leukemia is and guide future care.
Houston, TexasAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years
Hear when a new Relapsed Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed acute myeloid leukemia?
- Yes. Clin2 currently lists 284 recruiting relapsed acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.